Mechanism of Action of Bu-Fei-Yi-Shen Formula in Treating Chronic Obstructive Pulmonary Disease Based on Network Pharmacology Analysis and Molecular Docking Validation

Abstract

Objective. To explore the mechanism of action of Bu-Fei-Yi-Shen formula (BFYSF) in treating chronic obstructive pulmonary disease (COPD) based on network pharmacology analysis and molecular docking validation. Methods. First of all, the pharmacologically active ingredients and corresponding targets in BFYSF were mined by the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, the analysis platform, and literature review. Subsequently, the COPD-related targets (including the pathogenic targets and known therapeutic targets) were identified through the TTD, CTD, DisGeNet, and GeneCards databases. Thereafter, Cytoscape was employed to construct the candidate component-target network of BFYSF in the treatment of COPD. Moreover, the cytoHubba plug-in was utilized to calculate the topological parameters of nodes in the network; then, the core components and core targets of BFYSF in the treatment of COPD were extracted according to the degree value (greater than or equal to the median degree values for all nodes in the network) to construct the core network. Further, the Autodock vina software was adopted for molecular docking study on the core active ingredients and core targets, so as to verify the above-mentioned network pharmacology analysis results. Finally, the Omicshare database was applied in enrichment analysis of the biological functions of core targets and the involved signaling pathways. Results. In the core component-target network of BFYSF in treating COPD, there were 30 active ingredients and 37 core targets. Enrichment analysis suggested that these 37 core targets were mainly involved in the regulation of biological functions, such as response to biological and chemical stimuli, multiple cellular life processes, immunity, and metabolism. Besides, multiple pathways, including IL-17, Toll-like receptor (TLR), TNF, and HIF-1, played certain roles in the effect of BFYSF on treating COPD. Conclusion. BFYSF can treat COPD through the multicomponent, multitarget, and multipathway synergistic network, which provides basic data for intensively exploring the mechanism of action of BFYSF in treating COPD.

Mechanisms Underlying the Action of Ziziphi Spinosae Semen in the Treatment of Insomnia: A Study Involving Network Pharmacology and Experimental Validation

“…com/). We then performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses for the core targets and identified the key biological functions (biological processes, molecular functions, and cellular components) and related signaling pathways (Wu et al, 2020). Finally, an ingredient-target-pathway (I-T-P) network was generated by Cytoscape version 3.6.1 software, which featured a number of relationships, including the active chemical ingredients of ZSS, the core targets, and the enriched signaling pathways (An et al, 2020).…”

Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease?

“…In fact, BYF can treat patients with COPD via their multiple components. According to the network pharmacology analysis and molecular docking validation, a study showed that 48 components in BYF might act on 65 targets to exert the therapeutic effect, and the therapeutic process involved IL-17, Toll-like receptor (TLR) and TNF pathways ( Wu et al, 2020 ). Therefore, more attention should be drawn to BYF for therapeutic use in COPD.…”

Mechanism of Fei-Xian Formula in the Treatment of Pulmonary Fibrosis on the Basis of Network Pharmacology Analysis Combined with Molecular Docking Validation

“…Nonetheless, certain limitations should be noted in the present work [66], like the data-based network pharmacology, which made it impossible to examine whether all data were comprehensively collected and whether the criteria to select core components were completely accurate. Besides, the efficacy of additional components and effects of dosage should be further examined.…”